A randomized, double-blind, placebo-controlled, multicenter phase iii trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3): Updated safety results

Category Primary study
JournalEndocrine Reviews
Year 2011
This article has no abstract
Epistemonikos ID: 0a3aea7efe6866443677dbc7070a0e8d051677c5
First added on: Feb 04, 2025